In recent years, new agents have led to a paradigm shift in CLL patient care from chemo(immuno)therapy to targeted therapy, with unprecedented efficacy of the novel small molecule inhibitors of the B cell receptor (BCR) signaling or apoptosis pathways. Here, BCR is linked to B-cell chronic lymphocytic leukemia.